Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

Core Viewpoint - IMUNON, Inc. announces the acceptance of an abstract for a Phase 2 study involving IMNN-001, bevacizumab, and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients, to be presented at the ASCO annual meeting [1][2]. Group 1: Study Details - The abstract titled "A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy when administered in combination with bevacizumab and neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer" will be presented on June 3rd [2]. - The study is actively recruiting patients in the U.S. and is led by Dr. Amir A Jazaeri from The University of Texas MD Anderson Cancer Center [2][3]. Group 2: Funding and Clinical Significance - The study is substantially funded by Break Through Cancer, with MD Anderson as the leading clinical site, highlighting its importance in IMUNON's IL-12 gene therapy development for ovarian cancer [3]. - Dr. Sebastien Hazard, IMUNON's chief medical officer, emphasized the observed synergies in pre-clinical experiments with the combination of IMNN-001 and bevacizumab [3]. Group 3: Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms for effective responses to various diseases [4]. - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, currently in Phase 2 development [5]. - IMUNON is also entering a first-in-human study of its COVID-19 booster vaccine, IMNN-101, showcasing its commitment to advancing plasmid DNA technology [5].